These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

332 related items for PubMed ID: 20371240

  • 1. Group II metabotropic glutamate receptor agonists as a potential drug for schizophrenia.
    Chaki S.
    Eur J Pharmacol; 2010 Aug 10; 639(1-3):59-66. PubMed ID: 20371240
    [Abstract] [Full Text] [Related]

  • 2. Metabotropic glutamate2/3 (mGlu2/3) receptors, schizophrenia and cognition.
    Marek GJ.
    Eur J Pharmacol; 2010 Aug 10; 639(1-3):81-90. PubMed ID: 20371229
    [Abstract] [Full Text] [Related]

  • 3. [Evidence on the key role of the metabotrobic glutamatergic receptors in the pathogenesis of schizophrenia: a "breakthrough" in pharmacological treatment].
    Pannese R, Minichino A, Pignatelli M, Delle Chiaie R, Biondi M, Nicoletti F.
    Riv Psichiatr; 2012 Aug 10; 47(2):149-69. PubMed ID: 22622251
    [Abstract] [Full Text] [Related]

  • 4. Metabotropic glutamate mGlu1 receptor stimulation and blockade: therapeutic opportunities in psychiatric illness.
    Lesage A, Steckler T.
    Eur J Pharmacol; 2010 Aug 10; 639(1-3):2-16. PubMed ID: 20371230
    [Abstract] [Full Text] [Related]

  • 5. Metabotropic glutamate receptor 7: at the interface of cognition and emotion.
    O'Connor RM, Finger BC, Flor PJ, Cryan JF.
    Eur J Pharmacol; 2010 Aug 10; 639(1-3):123-31. PubMed ID: 20371242
    [Abstract] [Full Text] [Related]

  • 6. Group II metabotropic glutamate receptor agonists and positive allosteric modulators as novel treatments for schizophrenia.
    Fell MJ, McKinzie DL, Monn JA, Svensson KA.
    Neuropharmacology; 2012 Mar 10; 62(3):1473-83. PubMed ID: 21704048
    [Abstract] [Full Text] [Related]

  • 7. In vitro characterisation of the novel positive allosteric modulators of the mGlu₅ receptor, LSN2463359 and LSN2814617, and their effects on sleep architecture and operant responding in the rat.
    Gilmour G, Broad LM, Wafford KA, Britton T, Colvin EM, Fivush A, Gastambide F, Getman B, Heinz BA, McCarthy AP, Prieto L, Shanks E, Smith JW, Taboada L, Edgar DM, Tricklebank MD.
    Neuropharmacology; 2013 Jan 10; 64():224-39. PubMed ID: 22884720
    [Abstract] [Full Text] [Related]

  • 8. [Metabotropic glutamate receptors: new molecular targets in the treatment of neurological and psychiatric diseases].
    Luján-Miras R.
    Rev Neurol; 2013 Jan 10; 40(1):43-53. PubMed ID: 15696426
    [Abstract] [Full Text] [Related]

  • 9. Targeting of metabotropic glutamate receptors for the treatment of schizophrenia.
    Chaki S, Hikichi H.
    Curr Pharm Des; 2011 Jan 10; 17(2):94-102. PubMed ID: 21355835
    [Abstract] [Full Text] [Related]

  • 10. Recent patents on positive allosteric modulators of the metabotropic glutamate 5 receptor as a potential treatment for schizophrenia.
    Kanuma K, Aoki T, Shimazaki Y.
    Recent Pat CNS Drug Discov; 2010 Jan 10; 5(1):23-34. PubMed ID: 19832691
    [Abstract] [Full Text] [Related]

  • 11. [Targeting metabotropic glutamate receptors to develop novel antipsychotics].
    Chaki S, Yoshida S, Okuyama S.
    Nihon Shinkei Seishin Yakurigaku Zasshi; 2010 Nov 10; 30(5-6):207-13. PubMed ID: 21226317
    [Abstract] [Full Text] [Related]

  • 12. Modulation by group I mGLU receptor activation and group III mGLU receptor blockade of locomotor responses induced by D1-like and D2-like receptor agonists in the nucleus accumbens.
    Rouillon C, Degoulet M, Chevallier K, Abraini JH, David HN.
    Brain Res; 2008 Mar 10; 1198():44-54. PubMed ID: 18261716
    [Abstract] [Full Text] [Related]

  • 13. Pharmacological effects of metabotropic glutamate receptor ligands on prepulse inhibition in DBA/2J mice.
    Hikichi H, Nishino M, Fukushima M, Satow A, Maehara S, Kawamoto H, Ohta H.
    Eur J Pharmacol; 2010 Aug 10; 639(1-3):99-105. PubMed ID: 20371235
    [Abstract] [Full Text] [Related]

  • 14. Regulation of phosphoinositide turnover in neonatal rat cerebral cortex by group I- and II- selective metabotropic glutamate receptor agonists.
    Mistry R, Golding N, Challiss RA.
    Br J Pharmacol; 1998 Feb 10; 123(3):581-9. PubMed ID: 9504400
    [Abstract] [Full Text] [Related]

  • 15. Metabotropic glutamate receptors as novel targets for anxiety and stress disorders.
    Swanson CJ, Bures M, Johnson MP, Linden AM, Monn JA, Schoepp DD.
    Nat Rev Drug Discov; 2005 Feb 10; 4(2):131-44. PubMed ID: 15665858
    [Abstract] [Full Text] [Related]

  • 16. Metabotropic glutamate receptor ligands as possible anxiolytic and antidepressant drugs.
    Palucha A, Pilc A.
    Pharmacol Ther; 2007 Jul 10; 115(1):116-47. PubMed ID: 17582504
    [Abstract] [Full Text] [Related]

  • 17. Comparison of the mGlu(5) receptor positive allosteric modulator ADX47273 and the mGlu(2/3) receptor agonist LY354740 in tests for antipsychotic-like activity.
    Schlumberger C, Pietraszek M, Gravius A, Klein KU, Greco S, Morè L, Danysz W.
    Eur J Pharmacol; 2009 Nov 25; 623(1-3):73-83. PubMed ID: 19765575
    [Abstract] [Full Text] [Related]

  • 18. Group II metabotropic glutamate receptors reduce excitatory but not inhibitory neurotransmission in rat barrel cortex in vivo.
    Cahusac PM, Wan H.
    Neuroscience; 2007 Apr 25; 146(1):202-12. PubMed ID: 17346894
    [Abstract] [Full Text] [Related]

  • 19. The difference in effect of mGlu2/3 and mGlu5 receptor agonists on cognitive impairment induced by MK-801.
    Vales K, Svoboda J, Benkovicova K, Bubenikova-Valesova V, Stuchlik A.
    Eur J Pharmacol; 2010 Aug 10; 639(1-3):91-8. PubMed ID: 20371226
    [Abstract] [Full Text] [Related]

  • 20. Glutamatergic neurotransmission modulators as emerging new drugs for schizophrenia.
    Heresco-Levy U.
    Expert Opin Emerg Drugs; 2005 Nov 10; 10(4):827-44. PubMed ID: 16262565
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.